Loading...
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Domchek, S Postel-Vinay, S Im, SA Park, YH Delord, JP Italiano, A Alexandre, J You, B Bastian, S Krebs, Matthew G
Domchek, S
Postel-Vinay, S
Im, SA
Park, YH
Delord, JP
Italiano, A
Alexandre, J
You, B
Bastian, S
Krebs, Matthew G
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Domchek S, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. 1191O Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Annals of Oncology. 2019;30(Supplement_5):477.